Cargando…

Untargeted lipidomic analysis and network pharmacology for parthenolide treated papillary thyroid carcinoma cells

BACKGROUND: With fast rising incidence, papillary thyroid carcinoma (PTC) is the most common head and neck cancer. Parthenolide, isolated from traditional Chinese medicine, inhibits various cancer cells, including PTC cells. The aim was to investigate the lipid profile and lipid changes of PTC cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Le-Tian, Li, Tie-Jun, Li, Ming-Lin, Luo, Han-Yong, Wang, Yi-Bing, Wang, Jia-He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123985/
https://www.ncbi.nlm.nih.gov/pubmed/37095470
http://dx.doi.org/10.1186/s12906-023-03944-7
_version_ 1785029758761828352
author Huang, Le-Tian
Li, Tie-Jun
Li, Ming-Lin
Luo, Han-Yong
Wang, Yi-Bing
Wang, Jia-He
author_facet Huang, Le-Tian
Li, Tie-Jun
Li, Ming-Lin
Luo, Han-Yong
Wang, Yi-Bing
Wang, Jia-He
author_sort Huang, Le-Tian
collection PubMed
description BACKGROUND: With fast rising incidence, papillary thyroid carcinoma (PTC) is the most common head and neck cancer. Parthenolide, isolated from traditional Chinese medicine, inhibits various cancer cells, including PTC cells. The aim was to investigate the lipid profile and lipid changes of PTC cells when treated with parthenolide. METHODS: Comprehensive lipidomic analysis of parthenolide treated PTC cells was conducted using a UHPLC/Q-TOF–MS platform, and the changed lipid profile and specific altered lipid species were explored. Network pharmacology and molecular docking were performed to show the associations among parthenolide, changed lipid species, and potential target genes. RESULTS: With high stability and reproducibility, a total of 34 lipid classes and 1736 lipid species were identified. Lipid class analysis indicated that parthenolide treated PTC cells contained higher levels of fatty acid (FA), cholesterol ester (ChE), simple glc series 3 (CerG3) and lysophosphatidylglycerol (LPG), lower levels of zymosterol (ZyE) and Monogalactosyldiacylglycerol (MGDG) than controlled ones, but with no significant differences. Several specific lipid species were changed significantly in PTC cells treated by parthenolide, including the increasing of phosphatidylcholine (PC) (12:0e/16:0), PC (18:0/20:4), CerG3 (d18:1/24:1), lysophosphatidylethanolamine (LPE) (18:0), phosphatidylinositol (PI) (19:0/20:4), lysophosphatidylcholine (LPC) (28:0), ChE (22:6), and the decreasing of phosphatidylethanolamine (PE) (16:1/17:0), PC (34:1) and PC (16:0p/18:0). Four key targets (PLA2G4A, LCAT, LRAT, and PLA2G2A) were discovered when combining network pharmacology and lipidomics. Among them, PLA2G2A and PLA2G4A were able to bind with parthenolide confirmed by molecular docking. CONCLUSIONS: The changed lipid profile and several significantly altered lipid species of parthenolide treated PTC cells were observed. These altered lipid species, such as PC (34:1), and PC (16:0p/18:0), may be involved in the antitumor mechanisms of parthenolide. PLA2G2A and PLA2G4A may play key roles when parthenolide treated PTC cells. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12906-023-03944-7.
format Online
Article
Text
id pubmed-10123985
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101239852023-04-25 Untargeted lipidomic analysis and network pharmacology for parthenolide treated papillary thyroid carcinoma cells Huang, Le-Tian Li, Tie-Jun Li, Ming-Lin Luo, Han-Yong Wang, Yi-Bing Wang, Jia-He BMC Complement Med Ther Research BACKGROUND: With fast rising incidence, papillary thyroid carcinoma (PTC) is the most common head and neck cancer. Parthenolide, isolated from traditional Chinese medicine, inhibits various cancer cells, including PTC cells. The aim was to investigate the lipid profile and lipid changes of PTC cells when treated with parthenolide. METHODS: Comprehensive lipidomic analysis of parthenolide treated PTC cells was conducted using a UHPLC/Q-TOF–MS platform, and the changed lipid profile and specific altered lipid species were explored. Network pharmacology and molecular docking were performed to show the associations among parthenolide, changed lipid species, and potential target genes. RESULTS: With high stability and reproducibility, a total of 34 lipid classes and 1736 lipid species were identified. Lipid class analysis indicated that parthenolide treated PTC cells contained higher levels of fatty acid (FA), cholesterol ester (ChE), simple glc series 3 (CerG3) and lysophosphatidylglycerol (LPG), lower levels of zymosterol (ZyE) and Monogalactosyldiacylglycerol (MGDG) than controlled ones, but with no significant differences. Several specific lipid species were changed significantly in PTC cells treated by parthenolide, including the increasing of phosphatidylcholine (PC) (12:0e/16:0), PC (18:0/20:4), CerG3 (d18:1/24:1), lysophosphatidylethanolamine (LPE) (18:0), phosphatidylinositol (PI) (19:0/20:4), lysophosphatidylcholine (LPC) (28:0), ChE (22:6), and the decreasing of phosphatidylethanolamine (PE) (16:1/17:0), PC (34:1) and PC (16:0p/18:0). Four key targets (PLA2G4A, LCAT, LRAT, and PLA2G2A) were discovered when combining network pharmacology and lipidomics. Among them, PLA2G2A and PLA2G4A were able to bind with parthenolide confirmed by molecular docking. CONCLUSIONS: The changed lipid profile and several significantly altered lipid species of parthenolide treated PTC cells were observed. These altered lipid species, such as PC (34:1), and PC (16:0p/18:0), may be involved in the antitumor mechanisms of parthenolide. PLA2G2A and PLA2G4A may play key roles when parthenolide treated PTC cells. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12906-023-03944-7. BioMed Central 2023-04-24 /pmc/articles/PMC10123985/ /pubmed/37095470 http://dx.doi.org/10.1186/s12906-023-03944-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Huang, Le-Tian
Li, Tie-Jun
Li, Ming-Lin
Luo, Han-Yong
Wang, Yi-Bing
Wang, Jia-He
Untargeted lipidomic analysis and network pharmacology for parthenolide treated papillary thyroid carcinoma cells
title Untargeted lipidomic analysis and network pharmacology for parthenolide treated papillary thyroid carcinoma cells
title_full Untargeted lipidomic analysis and network pharmacology for parthenolide treated papillary thyroid carcinoma cells
title_fullStr Untargeted lipidomic analysis and network pharmacology for parthenolide treated papillary thyroid carcinoma cells
title_full_unstemmed Untargeted lipidomic analysis and network pharmacology for parthenolide treated papillary thyroid carcinoma cells
title_short Untargeted lipidomic analysis and network pharmacology for parthenolide treated papillary thyroid carcinoma cells
title_sort untargeted lipidomic analysis and network pharmacology for parthenolide treated papillary thyroid carcinoma cells
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123985/
https://www.ncbi.nlm.nih.gov/pubmed/37095470
http://dx.doi.org/10.1186/s12906-023-03944-7
work_keys_str_mv AT huangletian untargetedlipidomicanalysisandnetworkpharmacologyforparthenolidetreatedpapillarythyroidcarcinomacells
AT litiejun untargetedlipidomicanalysisandnetworkpharmacologyforparthenolidetreatedpapillarythyroidcarcinomacells
AT liminglin untargetedlipidomicanalysisandnetworkpharmacologyforparthenolidetreatedpapillarythyroidcarcinomacells
AT luohanyong untargetedlipidomicanalysisandnetworkpharmacologyforparthenolidetreatedpapillarythyroidcarcinomacells
AT wangyibing untargetedlipidomicanalysisandnetworkpharmacologyforparthenolidetreatedpapillarythyroidcarcinomacells
AT wangjiahe untargetedlipidomicanalysisandnetworkpharmacologyforparthenolidetreatedpapillarythyroidcarcinomacells